ArticleCureus2024
A Retrospective Study on the Expression of E-Cadherin in Endometrial Carcinoma.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Expression profiles of E-cadherin and N-cadherin in endometriosis and other gynecological diseases towards targeted treatment: a systematic review.Obstetrics & gynecology science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
E-cadherin is a cell adhesion molecule crucial for maintaining cellular integrity and survival. E-cadherin is the focus of this study, which aims to evaluate its immunohistochemical staining patterns in endometrial carcinoma (EC). Material and methods In this retrospective study, 25 formalin-fixed, paraffin-embedded tissue blocks of EC were retrieved from the Department of Pathology at Saveetha Medical College. These samples, collected between September 2020 and May 2023, were identified using unique histopathology numbers. Results The analysis revealed that E-cadherin expression decreased as the endometrial tissue progressed from normal to carcinoma. This reduction was more pronounced in cancers with greater depth of invasion and in more advanced stages compared to those with less invasive depth and earlier stages. Additionally, E-cadherin expression was higher in grade 1 tumors but became heterogeneous or negative in grade 3 tumors. Conclusion The downregulation of E-cadherin is likely due to disruptions in the cadherin-catenin complex, which is linked to the potential for local and distant metastasis in cancer. This study underscores the significance of cell adhesion molecule expression in predicting the prognosis of EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.